ストックスクリーナーアプリを入手
5.87
3.29%
-0.20
アフターアワーズ：
5.75
-0.12
-2.04%
前日終値:
$6.07
開ける：
$6.09
24時間の取引高:
1.13M
Relative Volume:
0.72
時価総額：
$1.20B
収益：
-
当期純損益:
$-118.84M
株価収益率:
-10.98
EPS:
-0.5344
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
-1.18%
1か月 パフォーマンス:
+11.81%
6か月 パフォーマンス:
+63.06%
1年 パフォーマンス:
+100.34%
1日の値動き範囲:
$5.83
$6.1603
1週間の範囲:
$5.48
$6.24
52週間の値動き範囲:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.87 | 1.24B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
FDA extends review of Savara’s molgramostim application - Investing.com
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Savara to present molgramostim data at ATS conference in May - Investing.com
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - National Today
Savara to present molgramostim data at ATS conference in May By Investing.com - Investing.com Australia
Savara Inc. (NASDAQ: SVRA) proxy: MOLBREEVI FDA date, equity and vote items - Stock Titan
Aug PreEarnings: Why is Savara Inc stock going downInsider Buying & Daily Stock Momentum Reports - baoquankhu1.vn
Savara advances MOLBREEVI reviews in US., Europe, UK - MSN
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. - MyChesCo
Street Watch: Can Savara Inc withstand a market correctionShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy - simplywall.st
Savara (SVRA) Advances with Regulatory Reviews for Molbreevi - GuruFocus
Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) - marketscreener.com
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
SVRA Technical Analysis & Stock Price Forecast - Intellectia AI
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st
Guggenheim Keeps Their Buy Rating on Savara (SVRA) - The Globe and Mail
Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com Australia
Citizens reiterates Savara stock rating on regulatory progress - Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - Investing.com South Africa
Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus
Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com Canada
Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com UK
Jefferies sees Savara stock approval odds at 90% for rare lung drug By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget
EMA validates Savara’s MOLBREEVI application for autoimmune PAP - Investing.com
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Savara grants inducement equity awards to new employee - MSN
Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
High Growth Tech Stocks To Watch In The US March 2026 - Sahm
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Savara’s MOLBREEVI BLA Receives FDA Priority Review - msn.com
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):